Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP14 | P54578 | 12/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11168863 | 0.88 | USP14 (0.41) | USP14MEN1KMT2A | |
| SCHEMBL24850545 | 0.84 | TDP1 (0.34) | USP14TDP1MEN1KMT2A | |
| SCHEMBL14038217 | 0.76 | USP14 (0.38) | USP14 | |
| SCHEMBL23671801 | 0.75 | LMNA (0.54) | USP14 | |
| SCHEMBL23467552 | 0.75 | LMNA (0.54) | USP14 | |
| SCHEMBL23133699 | 0.75 | LMNA (0.54) | USP14 | |
| SCHEMBL23671794 | 0.75 | LMNA (0.54) | USP14 | |
| SCHEMBL10362732 | 0.75 | LMNA (0.54) | USP14 | |
| SCHEMBL14038188 | 0.74 | — | — | |
| SCHEMBL12523561 | 0.74 | KDM1A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303204-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-09 | — | — | US | disclosed |
| US-8785640-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140088141-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-27 | — | — | US | disclosed |
| US-20130303570-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED | 2013-11-14 | — | — | US | disclosed |
| US-20130040986-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED | 2013-02-14 | — | — | US | disclosed |
| US-8314239-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-11-20 | — | — | US | disclosed |
| US-20100113509-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040986-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1G, SCNN1B | USP14 4248/4885TDP1 4749/4885MEN1 4440/4885 |
| US-20130303570-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1G, SCNN1B | USP14 4248/4885TDP1 4749/4885MEN1 4440/4885 |
| US-20140088141-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | USP14 4248/4885TDP1 4749/4885MEN1 4440/4885 |
| US-20140303204-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | USP14 4248/4885TDP1 4749/4885MEN1 4440/4885 |
| US-20100113509-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | USP14 4248/4885TDP1 4749/4885MEN1 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.